SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Gufic Biosciences - Quaterly Results

13 Aug 2025 Evaluate
The June 2025 quarter revenue stood at Rs. 2269.12 millions, up 11.88% as compared to Rs. 2028.12 millions during the corresponding quarter last year.A big decline of -42.13% was reported for the quarter ended June 2025 to Rs. 120.72  millions from Rs. 208.59 millions of corresponding previous quarter.Operating Profit reported a sharp decline to 332.29 millions from 370.37 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202506 202406 % Var 202506 202406 % Var 202503 202403 % Var
Sales 2269.12 2028.12 11.88 2269.12 2028.12 11.88 8198.06 8066.66 1.63
Other Income 8.94 12.55 -28.76 8.94 12.55 -28.76 36.15 21.77 66.05
PBIDT 332.29 370.37 -10.28 332.29 370.37 -10.28 1386.03 1480.48 -6.38
Interest 92.34 46.24 99.70 92.34 46.24 99.70 231.12 153.60 50.47
PBDT 239.95 324.13 -25.97 239.95 324.13 -25.97 1154.91 1326.88 -12.96
Depreciation 77.19 43.05 79.30 77.19 43.05 79.30 210.64 170.17 23.78
PBT 162.76 281.08 -42.09 162.76 281.08 -42.09 944.27 1156.71 -18.37
TAX 42.04 72.49 -42.01 42.04 72.49 -42.01 244.95 295.36 -17.07
Deferred Tax 19.84 2.49 696.79 19.84 2.49 696.79 57.51 31.65 81.71
PAT 120.72 208.59 -42.13 120.72 208.59 -42.13 699.32 861.35 -18.81
Equity 100.28 100.28 0.00 100.28 100.28 0.00 100.28 100.28 0.00
PBIDTM(%) 14.64 18.26 -19.81 14.64 18.26 -19.81 16.91 18.35 -7.88

Gufic Biosciences Share Price

301.30 -1.35 (-0.45%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×